You just read:

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

News provided by

Protagonist Therapeutics, Inc.

May 30, 2017, 07:00 ET